剂量组学风险模型预测放射性颞叶损伤并指导个体化调强放疗
本研究纳入5599例鼻咽癌患者,构建基于剂量分布的剂量组学风险模型,并与定量分析正常组织效应临床模型及Wen模型比较。剂量组学风险模型联合剂量组学特征、D1cc和年龄,在训练、验证、前瞻测试和外部测试队列中C指数分别为0.776、0.811、0.805和0.794,优于传统模型(均P<.001)。该模型能区分其他模型划分的同一风险类别患者(均P<.05),而其他模型无法区分剂量组学风险模型分类的人群(均P>.05)。
要点
- 剂量组学风险模型联合剂量组学特征、D1cc和年龄,C指数在训练、验证、前瞻测试和外部测试队列分别为0.776、0.811、0.805和0.794。
- 剂量组学风险模型优于定量分析正常组织效应临床模型和Wen模型(均P<.001)。
- 相同剂量体积直方图但剂量分布不同的两个模拟计划,剂量组学风险模型预测的无颞叶损伤生存率不同(均P≤.002)。
核心结论
- 剂量组学风险模型在预测放射性颞叶损伤风险方面优于传统模型,是精确预测放射性毒性并指导个体化调强放疗的有前景方法。
研究设计与样本
- 共纳入5599例鼻咽癌患者,训练队列2503例、验证队列1072例、前瞻测试队列988例、外部测试队列1036例。
- 基于计划CT提取影像组学特征、基于剂量分布提取剂量组学特征,构建预测无颞叶损伤生存的模型。
- 采用一致性指数(C-index)比较影像组学模型、剂量组学模型与定量分析正常组织效应临床模型及Wen模型的性能。
- 对30例随机选取患者的相同剂量体积直方图但不同剂量分布的模拟计划,采用Wilcoxon配对符号秩检验比较预测的无颞叶损伤生存率。
主要发现
- 影像组学特征基于30个选定的CT特征构建,剂量组学特征基于10个选定的剂量分布特征构建,均为无颞叶损伤生存的重要预测因子(均P<.001)。
- 影像组学特征的C指数较低。
- 剂量组学风险模型联合剂量组学特征、D1cc和年龄,C指数在训练、验证、前瞻测试和外部测试队列分别为0.776、0.811、0.805和0.794,优于定量分析正常组织效应临床模型和Wen模型(均P<.001)。
- 剂量组学风险模型能进一步区分其他模型划分的同一风险类别患者(均P<.05),而其他模型无法区分剂量组学风险模型分类的人群(均P>.05)。
- 相同剂量体积直方图但剂量分布不同的两个模拟计划,剂量组学风险模型预测的无颞叶损伤生存率不同(均P≤.002)。
关键数值与推荐
- 剂量组学风险模型联合剂量组学特征、D1cc和年龄,训练队列C指数0.776、验证队列0.811、前瞻测试队列0.805、外部测试队列0.794。
- 剂量组学风险模型与定量分析正常组织效应临床模型及Wen模型比较,均P<.001。
- 剂量组学风险模型区分其他模型同一风险类别患者,均P<.05;其他模型区分剂量组学风险模型分类人群,均P>.05。
- 相同剂量体积直方图不同剂量分布的模拟计划预测无颞叶损伤生存率比较,均P≤.002。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to assess the value of dose distribution-based dosiomics and planning computed tomography-based radiomics to predict radiation-induced temporal lobe injury (TLI) and guide individualized intensity modulated radiation therapy. METHODS AND MATERIALS: A total of 5599 nasopharyngeal carcinoma patients were enrolled, including 2503, 1072, 988, and 1036 patients in the training, validation, prospective test, and external test cohorts, respectively. The concordance index (C-index) was used to compare the performance of the radiomics and dosiomics models with that of the quantitative analyses of normal tissue effects in the clinic and Wen's models. The predicted TLI-free survival rates of redesigned simulated plans with the same dose-volume histogram but different dose distributions for same patient in a cohort of 30 randomly selected patients were compared by the Wilcoxon matched-pairs signed-rank test. RESULTS: The radiomics and dosiomics signatures were constructed based on 30 selected computed tomography features and 10 selected dose distribution features, respectively, which were important predictors of TLI-free survival (all P <.001). However, the radiomics signature had a low C-index. The dosiomics risk model combining the dosiomics signature, D1cc, and age had favorable performance, with C-index values of 0.776, 0.811, 0.805, and 0.794 in the training, validation, prospective test, and external test cohorts, respectively, which were better than those of the quantitative analyses of normal tissue effects in the clinic model and Wen's model (all P <.001). The dosiomics risk model can further distinguish patients in a same risk category divided by other models (all P <.05). Conversely, the other models were unable to separate populations classified by the dosiomics risk model (all P > .05). Two simulated plans with the same dose-volume histogram but different dose distributions had different TLI-free survival rates predicted by dosiomics risk model (all P ≤ .002). CONCLUSIONS: The dosiomics risk model was superior to traditional models in predicting the risk of TLI. This is a promising approach to precisely predict radiation-induced toxicities and guide individualized intensity modulated radiation therapy.
引用
- Yang SS, OuYang PY, Guo JG, et al. Dosiomics Risk Model for Predicting Radiation Induced Temporal Lobe Injury and Guiding Individual Intensity-Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022. PMID: 36462689. doi:10.1016/j.ijrobp.2022.11.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。